Vistusertib
Term · Oncology and biomedicine · MLC-T-ONC-017514
An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.
| Identifier | MLC-T-ONC-017514 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | mTOR kinase inhibitor AZD2014 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017514",
"term": "Vistusertib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Vistusertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.",
"synonyms": [
"mTOR kinase inhibitor AZD2014"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/vistusertib/"
}
Record 17,273 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.